ClinicalTrials.gg
Not yet recruitingNCT07593612TACTIC-HFUpdated May 18, 2026

TACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart Failure

A Phase 4 interventional study of Intravenous furosemide bolus injections and ACETAZOLAMIDE oral capsule in Acute Heart Failure (AHF), sponsored by Lucrecia Maria Burgos. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Lucrecia Maria Burgos · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing acetazolamide in Heart Failure — 6 open to participants now, 7 under way, 2 of them phase 3. Acetazolamide · Heart Failure.

Planned enrollment
9th of 14
60 · median 66
Started
2026
with 2 others
Phase 4
8 of 14
2 open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
Lucrecia Maria Burgos

Among the 14 studies testing acetazolamide in Heart Failure, this one is the 9th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 4, and was the 12th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 14 studies testing acetazolamide in Heart Failure are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About acetazolamide

Acetazolamide: first FDA approval 1953 (DIAMOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing acetazolamide in Heart Failure, or all of them as a file.
02

Study summary

TACTIC-HF is a prospective randomized crossover trial designed to compare three ambulatory diuretic strategies in patients with worsening heart failure treated in a specialized heart failure day-hospital program.

Participants will receive sequential treatment with:

  1. intravenous furosemide alone,
  2. intravenous furosemide combined with oral acetazolamide, and
  3. intravenous furosemide combined with oral hydrochlorothiazide.

The primary objective is to compare short-term natriuretic response between strategies. Secondary objectives include assessment of urine output, congestion parameters, and renal/electrolyte safety.

Each participant will undergo repeated outpatient treatment sessions separated by washout periods, with standardized clinical and laboratory monitoring performed during each visit.

The study aims to evaluate pragmatic and clinically applicable ambulatory decongestion strategies using approved therapies commonly available in real-world practice.

Read the detailed description

Heart failure congestion remains one of the leading causes of hospitalization and recurrent healthcare utilization worldwide. Although loop diuretics represent the cornerstone of decongestive therapy, many patients develop suboptimal diuretic response or diuretic resistance during the course of chronic heart failure.

Sequential nephron blockade strategies combining loop diuretics with agents acting at different tubular sites may enhance natriuresis and improve decongestion. Recent inpatient studies have suggested potential benefits of acetazolamide- and thiazide-based strategies; however, evidence regarding ambulatory worsening heart failure management remains limited.

TACTIC-HF is a prospective, single-center, randomized, open-label crossover trial evaluating three commonly used outpatient decongestion strategies in patients with worsening heart failure treated in a dedicated heart failure day-hospital setting.

Participants will sequentially receive:

  • intravenous furosemide alone,
  • intravenous furosemide plus oral acetazolamide,
  • intravenous furosemide plus oral hydrochlorothiazide.

Treatments will be administered during structured outpatient sessions with standardized monitoring and predefined washout intervals between treatment periods.

The primary endpoint is total urinary sodium excretion during the treatment session. Secondary endpoints include urine output, congestion-related parameters, and renal/electrolyte safety outcomes.

The study is designed as a pragmatic trial using approved therapies routinely available in clinical practice, with the objective of generating physiologically oriented evidence applicable to ambulatory heart failure care.

03

Conditions studied

  • Acute Heart Failure (AHF)

Browse trials for

Keywords

  • worsening heart failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years Chronic heart failure diagnosis according to current guideline definitions Ambulatory worsening heart failure requiring intravenous diuretic therapy in a specialized outpatient setting Evidence of clinical or objective congestion Chronic outpatient loop diuretic therapy Ability to comply with study procedures Written

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability or cardiogenic shock Requirement for immediate hospitalization Acute coronary syndrome, active infection, pulmonary embolism, or uncontrolled arrhythmia Severe electrolyte abnormalities Advanced renal failure requiring dialysis Pregnancy or breastfeeding or allergy to study medications Current treatment with acetazolamide or thiazide diuretics Any condition that, in the opinion of the investigators, would make study participation unsafe or interfere with study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Intravenous Furosemide

    Participants receive outpatient intravenous furosemide according to the study protocol during a structured ambulatory treatment session.

    Drug: Intravenous furosemide bolus injections

  • Experimental
    Intravenous Furosemide + Acetazolamide

    Participants receive outpatient intravenous furosemide combined with oral acetazolamide during a structured ambulatory treatment session

    Drug: Intravenous furosemide bolus injections · Drug: ACETAZOLAMIDE oral capsule

  • Experimental
    Intravenous Furosemide + Hydrochlorothiazide

    Participants receive outpatient intravenous furosemide combined with oral hydrochlorothiazide during a structured ambulatory treatment session

    Drug: Intravenous furosemide bolus injections · Drug: Hydrochlorothiazide (HCT)

Interventions

  • DrugIntravenous furosemide bolus injections

    Intravenous loop diuretic therapy administered during outpatient treatment sessions according to protocol-defined dosing categories.

  • DrugAcetazolamideStudies of AcetazolamideAcetazolamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral acetazolamide administered prior to intravenous loop diuretic therapy during outpatient treatment sessions

  • DrugHydrochlorothiazideStudies of HydrochlorothiazideHydrochlorothiazide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral hydrochlorothiazide administered prior to intravenous loop diuretic therapy during outpatient treatment sessions.

06

What researchers measure

Primary outcomes

  1. Total Urinary Sodium Excretion at 6 Hours

    Total urine volume collected during the outpatient treatment session

    Time frame: 6 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Abbo AR, Gruber A, Volis I, Aronson D, Girerd N, Lund Kristensen S, Zukermann R, Alberkant N, Sitnitsky E, Kruger A, Khasis P, Bravo E, Elad B, Helmer Levin L, Caspi O. Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intrapatient Comparison of 3 Diuretic Regimens (DEA-HF). JACC Heart Fail. 2024 Aug;12(8):1396-1405. doi: 10.1016/j.jchf.2024.04.014. Epub 2024 May 11. PubMed 38739124 ↗
  • Trullas JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sanchez-Marteles M, Conde-Martel A, Davila-Ramos MF, Llacer P, Salamanca-Bautista P, Perez-Silvestre J, Plasin MA, Cerqueiro JM, Gil P, Formiga F, Manzano L; CLOROTIC trial investigators. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023 Feb 1;44(5):411-421. doi: 10.1093/eurheartj/ehac689. PubMed 36423214 ↗
  • Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R, Blouard P, Troisfontaines P, Derthoo D, Smolders W, Bruckers L, Droogne W, Ter Maaten JM, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M; ADVOR Study Group. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022 Sep 29;387(13):1185-1195. doi: 10.1056/NEJMoa2203094. Epub 2022 Aug 27. PubMed 36027559 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jan 2027, 7 months later.

Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 7 months is below that.

Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 18, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jan 15, 2027
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07593612
Lead sponsor
Lucrecia Maria Burgos
Responsible party
Lucrecia Maria Burgos (MD, Instituto Cardiovascular de Buenos Aires) — Sponsor-investigator
First posted
May 18, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
May 18, 2026

Study contacts

Lucrecia Maria Burgos, MD
Contact
lburgos@icba.com.ar
541147877500

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetazolamide · Hydrochlorothiazide

Start the discussion